Etta Indu, Elballushi Ruaa, Kolesnyk Viktoriia, Sia Kim P, Rehman Sana, Arif Sehrish, Moonnumackel Sania J, Nair Arun
Department of Internal Medicine, Kakatiya Medical College, Warangal, IND.
School of Medicine, Royal College of Surgeons in Ireland - Medical University of Bahrain, Muharraq, BHR.
Cureus. 2023 Sep 18;15(9):e45454. doi: 10.7759/cureus.45454. eCollection 2023 Sep.
Multiple sclerosis (MS) is a chronic autoimmune neurological disorder that significantly impacts the central nervous system (CNS), which includes the brain and spinal cord. Approximately 2.8 million individuals are believed to be living with MS worldwide. The management of MS has evolved considerably over the years, offering a multitude of guidelines, diverse treatment options, and different approaches to signs and symptoms. The present systematic literature review serves as a comprehensive analysis of the current therapeutic options for MS. It provides a thorough literature review of Food and Drug Administration (FDA)-approved drugs comparing their various clinical end points while concurrently assessing their risk-benefit ratio. It also provides an extensive review of current guidelines and offers an in-depth examination of the different approaches to MS. Through this multifaceted approach, this paper facilitates easy access to available treatment options and aims to aid healthcare providers in decision-making as well as providing a foundation for future research aimed at enhancing treatment options for MS.
多发性硬化症（MS）是一种慢性自身免疫性神经疾病，会对包括脑和脊髓在内的中枢神经系统（CNS）产生重大影响。据信，全球约有280万人患有多发性硬化症。多年来，多发性硬化症的管理有了很大发展，提供了众多指南、多样的治疗选择以及针对症状和体征的不同方法。本系统文献综述对当前多发性硬化症的治疗选择进行了全面分析。它对美国食品药品监督管理局（FDA）批准的药物进行了全面的文献综述，比较了它们的各种临床终点，同时评估了它们的风险效益比。它还对当前指南进行了广泛综述，并对多发性硬化症的不同治疗方法进行了深入研究。通过这种多方面的方法，本文便于获取现有的治疗选择，旨在帮助医疗保健提供者进行决策，并为未来旨在增加多发性硬化症治疗选择的研究奠定基础。
